Demcizumab
Based on 1 Customer Validation
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.37%
- CAS No.: 1243262-17-0
- Masse moléculaire:145.36 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P99320
TarextumabAnti-Notch2/3 Monoclonal Antibody -
HY-P99258
BrontictuzumabNotch1 Inhibitor -
HY-137471
RBPJ Inhibitor-1RBPJ Inhibitor -
HY-P9904
AtezolizumabAnti-PD-L1 Antibody -
HY-P99575
Tarlatamabanti-DLL3/CD3 BiTE antibody -
HY-P99043
RovalpituzumabDLL3 Monoclonal Antibody -
HY-135145
LimantrafinNotch Inhibitor -
HY-15860
FLI-06Notch Inhibitor -
HY-P99377
NavicixizumabAnti-VEGF/DLL4 Antibody -
HY-15670
BMS-906024γ-secretase Inhibitor -
HY-120782
Yhhu-3792Notch Activator -
HY-100431
IMR-1Notch Inhibitor
Activité biologique
Description
Isotype
Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
DLL4
In Vitro
Demcizumab (0-100 μg/mL) binds to human DLL4 but not murine DLL4, and blocks DLL4 binding to Notch1 receptor in a FACS-binding assay[3].
Demcizumab (20 μg/mL, 48 h) reduces HES1 and DTX1 mRNA expression in PDTALL cells[4].
Demcizumab (0-80 μg/mL, 1 or 2 or 3 days) promotes cell death and early apoptosis in PDTALL13 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PDTALL13 (patient-derived T-ALL 13) cell
-
Concentration:0, 0.5, 1, 5, 10, 20, 40, 80 μg/mL
-
Incubation Time:1 or 2 or 3 days
-
Result:Dose-dependently inhibited cell viability.
In Vivo
Demcizumab is efficacious alone or in combination with Irinotecan (7.5 mg/kg) in OMP-C8 colon tumors[3].
Demcizumab (20 mg/kg/week, i.p.) increases mice survival in irradiated NRG mice injected PDTALL13 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:KRASWT and KRASMT CRC xenografts[2]
-
Dosage:10 mg/kg, together with Irinotecan (HY-16562) (7.5 mg/kg)
-
Administration:Intraperitoneal injection (i.p.), once a week
-
Result:Resulted in tumor regression at day 20.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
NP_061947.1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG2 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 HUVEC cells with Demcizumab (HY-P99261, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa (HY-P99002, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1243262-17-0
-
Appearance Liquid
-
Masse moléculaire 145.36 kDa
-
Color Colorless to light yellow
-
SMILES
[Demcizumab]
-
Synonyms
OMP 21M18
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Smith DC, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15;20(24):6295-303. [Content Brief]
[2]. Fischer M, et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011;71:1520-5. [Content Brief]
[3]. Hoey T, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168–77. [Content Brief]
[4]. Xiong H, et al. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021 Jan 1;11(4):1594-1608. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Demcizumab Related Classifications
HY-P99261 Related Classifications
Powered by Bioz